0000899243-20-028077.txt : 20201013 0000899243-20-028077.hdr.sgml : 20201013 20201013202102 ACCESSION NUMBER: 0000899243-20-028077 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20201001 FILED AS OF DATE: 20201013 DATE AS OF CHANGE: 20201013 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Driscoll Cindy CENTRAL INDEX KEY: 0001741269 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38541 FILM NUMBER: 201237811 MAIL ADDRESS: STREET 1: C/O MAGENTA THERAPEUTICS, INC. STREET 2: 50 HAMPSHIRE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Magenta Therapeutics, Inc. CENTRAL INDEX KEY: 0001690585 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY SQUARE STREET 2: 5TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-201-2700 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY SQUARE STREET 2: 5TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-10-01 0 0001690585 Magenta Therapeutics, Inc. MGTA 0001741269 Driscoll Cindy C/O MAGENTA THERAPEUTICS, INC. 100 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 0 1 0 0 See Remarks Stock Option (Right to Buy) 4.84 2027-09-26 Common Stock 42899 D Stock Option (Right to Buy) 7.71 2028-01-30 Common Stock 13235 D Stock Option (Right to Buy) 9.49 2028-05-08 Common Stock 47406 D Stock Option (Right to Buy) 7.13 2029-02-04 Common Stock 40000 D Stock Option (Right to Buy) 12.28 2030-02-09 Common Stock 32000 D Restricted Stock Units Common Stock 20000 D This option is currently exercisable with respect to 28,385 shares of Magenta Therapeutics, Inc. common stock, par value $0.001 per share ("Common Stock"). The remaining unvested options shall vest and become exercisable in three equal quarterly installments beginning December 26, 2020. This option is currently exercisable with respect to 9,097 shares of Common Stock. The remaining unvested options shall vest and become exercisable in five equal quarterly installments beginning January 1, 2021. This option is currently exercisable with respect to 27,648 shares of Common Stock. The remaining unvested options shall vest and become exercisable in 20 equal monthly installments beginning October 20, 2020. This option is currently exercisable with respect to 17,500 shares of Common Stock. The remaining unvested options shall vest and become exercisable in 9 equal quarterly installments beginning January 1, 2021. This option is currently exercisable with respect to 6,000 shares of Common Stock. The remaining unvested options shall vest and become exercisable in 13 equal quarterly installments beginning January 1, 2021. The restricted stock units shall vest in three equal annual installments beginning on September 30, 2021. Each restricted stock unit represents a contingent right to receive one share of Common Stock. Treasurer & Vice President, Finance Exhibit 24.1: Power of Attorney /s/ Zoran Zdraveski, Attorney-in-Fact for Cindy Driscoll 2020-10-13 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

                               Power of Attorney

     Know all by these presents, that the undersigned hereby constitutes and
appoints each of Zoran Zdraveski and Jason Gardner, signing singly, and with
full power of substitution, as the undersigned's true and lawful attorney-in-
fact to:

          (1) execute for and on behalf of the undersigned, in the undersigned's
          capacity as an officer and/or director of Magenta Therapeutics, Inc.,
          a Delaware corporation (the "Company"), from time to time the
          following Securities and Exchange Commission (the "SEC") forms: Forms
          3, 4, and 5 in accordance with Section 16(a) of the Securities
          Exchange Act of 1934, as amended (the "Exchange Act"), and the rules
          thereunder;

          (2) do and perform any and all acts for and on behalf of the
          undersigned which may be necessary or desirable to complete and
          execute any such Form 3, 4, or 5, complete and execute any amendment
          or amendments thereto, and timely file such form with the SEC and any
          stock exchange or similar authority; and

          (3) take any other action of any type whatsoever in connection with
          the foregoing which, in the opinion of such attorney-in-fact, may be
          of benefit to, in the best interest of, or legally required by, the
          undersigned, it being understood that the documents executed by such
          attorney-in-fact on behalf of the undersigned pursuant to this Power
          of Attorney shall be in such form and shall contain such terms and
          conditions as such attorney-in-fact may approve in such attorney-in-
          fact's discretion.

     The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming, nor
is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.

     This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in- fact. This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an officer of
the Company. This Power of Attorney may be filed with the SEC as a confirming
statement of the authority granted herein.

     IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 13th day of October, 2020.

              /s/ Cindy Driscoll
              ------------------------

Printed Name: Cindy Driscoll
              ------------------------